DK3302437T4 - Stabile cannabinoidformuleringer - Google Patents

Stabile cannabinoidformuleringer

Info

Publication number
DK3302437T4
DK3302437T4 DK16800777.1T DK16800777T DK3302437T4 DK 3302437 T4 DK3302437 T4 DK 3302437T4 DK 16800777 T DK16800777 T DK 16800777T DK 3302437 T4 DK3302437 T4 DK 3302437T4
Authority
DK
Denmark
Prior art keywords
cannabinoid formulations
stable cannabinoid
stable
formulations
cannabinoid
Prior art date
Application number
DK16800777.1T
Other languages
English (en)
Other versions
DK3302437T3 (da
Inventor
Kiran Kumar Vangara
Huaguang Li
Ningxin Yan
Hung Q Nguyen
Venkat R Goskonda
Original Assignee
Fresh Cut Dev Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57393689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3302437(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/724,351 external-priority patent/US11224660B2/en
Priority claimed from US14/815,936 external-priority patent/US11331279B2/en
Application filed by Fresh Cut Dev Llc filed Critical Fresh Cut Dev Llc
Publication of DK3302437T3 publication Critical patent/DK3302437T3/da
Application granted granted Critical
Publication of DK3302437T4 publication Critical patent/DK3302437T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
DK16800777.1T 2015-05-28 2016-05-27 Stabile cannabinoidformuleringer DK3302437T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/724,351 US11224660B2 (en) 2014-05-29 2015-05-28 Stable cannabinoid formulations
US14/815,936 US11331279B2 (en) 2014-05-29 2015-07-31 Stable cannabinoid formulations
PCT/US2016/034565 WO2016191651A1 (en) 2015-05-28 2016-05-27 Stable cannabinoid formulations

Publications (2)

Publication Number Publication Date
DK3302437T3 DK3302437T3 (da) 2023-01-09
DK3302437T4 true DK3302437T4 (da) 2026-02-23

Family

ID=57393689

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16800777.1T DK3302437T4 (da) 2015-05-28 2016-05-27 Stabile cannabinoidformuleringer

Country Status (7)

Country Link
EP (2) EP4193990A1 (da)
JP (2) JP6899506B2 (da)
AU (3) AU2016267585C1 (da)
CA (1) CA2986268C (da)
DK (1) DK3302437T4 (da)
ES (1) ES2938560T3 (da)
WO (1) WO2016191651A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
WO2018200024A1 (en) 2017-04-27 2018-11-01 Insys Development Company, Inc. Stable cannabinoid formulations
AU2018286647B2 (en) 2017-06-19 2024-03-28 Zelira Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
JP2021500312A (ja) * 2017-09-15 2021-01-07 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 自閉症の治療のための組成物および方法
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
US20210290562A1 (en) 2018-12-11 2021-09-23 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20200375911A1 (en) * 2019-06-03 2020-12-03 Fresh Cut Development, Llc Cannabidiol nanocrystal compositions
ES3060000T3 (en) * 2019-09-09 2026-03-24 Cardiol Therapeutics Inc Stable medicinal cannabidiol compositions
CA3157812C (en) * 2019-10-25 2024-10-22 Cardiol Therapeutics Inc. CANNABIDIOL COMPOSITIONS INTENDED FOR USE IN THE TREATMENT OF HEART CONDITIONS
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP2023527454A (ja) * 2020-05-29 2023-06-28 セレシン・インコーポレーテッド 中鎖トリグリセリドを使用して点頭てんかんを処置する方法
KR20230066372A (ko) * 2020-09-24 2023-05-15 니코벤처스 트레이딩 리미티드 포뮬레이션
MX2023006686A (es) * 2020-12-07 2023-06-19 Cardiol Therapeutics Inc Composiciones orales estables de cannabidiol.
WO2022149144A1 (en) * 2021-01-11 2022-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Stable efficient cosmetic preparations
SMT202500224T1 (it) * 2021-04-12 2025-07-22 Curantis Ug Metodi per ottimizzare il trattamento di disturbi mentali con cannabidiolo e composizioni farmaceutiche comprendenti cannabidiolo
GB2617823A (en) * 2022-04-11 2023-10-25 Chanelle Mccoy Cbd Ltd A cannabidiol oil and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
NZ527289A (en) 2001-02-14 2005-05-27 Gw Pharma Ltd Lipophilic medicaments and their administration via mucosal surfaces
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
MX2007007038A (es) * 2004-12-09 2008-03-07 Insys Therapeutics Inc Formulacion de dronabinol en temperatura ambiente.
US20140357708A1 (en) 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
CA2618705C (en) 2005-11-07 2014-04-22 Murty Pharmaceuticals, Inc. Improved delivery of tetrahydrocannabinol
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
WO2012071389A2 (en) * 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
AU2015266897B2 (en) * 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
MX2023006686A (es) 2020-12-07 2023-06-19 Cardiol Therapeutics Inc Composiciones orales estables de cannabidiol.

Also Published As

Publication number Publication date
AU2022201441A1 (en) 2022-03-24
EP3302437A4 (en) 2018-12-05
DK3302437T3 (da) 2023-01-09
AU2024266845A1 (en) 2024-12-12
AU2016267585A1 (en) 2017-11-30
WO2016191651A1 (en) 2016-12-01
EP3302437B2 (en) 2025-12-24
JP7374951B2 (ja) 2023-11-07
CA2986268C (en) 2024-01-02
JP6899506B2 (ja) 2021-07-07
EP3302437B1 (en) 2022-11-16
EP4193990A1 (en) 2023-06-14
EP3302437B8 (en) 2022-12-21
AU2016267585B2 (en) 2021-12-16
ES2938560T3 (es) 2023-04-12
AU2016267585C1 (en) 2023-02-16
AU2022201441B2 (en) 2024-08-29
EP3302437A1 (en) 2018-04-11
JP2018516281A (ja) 2018-06-21
CA2986268A1 (en) 2016-12-01
JP2021107438A (ja) 2021-07-29

Similar Documents

Publication Publication Date Title
IL289084A (en) Cannabinoid formulations
DK3302437T4 (da) Stabile cannabinoidformuleringer
EP3703672A4 (en) CANNABINOID FORMULATIONS
EP3148589C0 (en) STABLE CANNABINOID FORMULATIONS
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
EP3615079A4 (en) STABLE CANNABINOID FORMULATIONS
IL255028A0 (en) Hydroponics
EP3337502A4 (en) STABLE ANTI-IFNAR1 FORMULATION
MA50657A (fr) Formulations de niraparib
PL3368014T3 (pl) Nowe preparaty kannabinoidów
FR3039337B1 (fr) Motoreducteur compact
DK3163339T3 (da) Polariseringsbevarende multikernefiber
DK3226894T3 (da) Stabile flydende vacciniavirus-formuleringer
EP3367997A4 (en) Novel occlusive formulations
LT3386954T (lt) Dimeriniai kontrastiniai agentai
EP3462885A4 (en) STABLE CANNABINOID FORMULATIONS
EP3364945C0 (en) SOLID FORMULATION
EP3541200C0 (en) POWDERED FORMULATIONS
EP3383912A4 (en) TOPICAL FORMULATIONS
EP3308781A4 (en) BLOOD PRESSURE CENTER
HUE063178T2 (hu) Kopanlizib formulációi
EP3349766A4 (en) ANTIHORMORRHAGIC COMPOSITIONS
DE112016003293A5 (de) Feuerlöscher
IL272167A (en) Hemopexin formulations